DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Gadgeeel SM. et al.
OAK, a randomized Ph III study of atezolizumab vs docetaxel in patients with advanced NSCLC: results from subgroup analyses.
WCLC; 2016 abstr. PL04a.02
We do not assume any responsibility for the contents of the web pages of other providers.